Secondary malignant neoplasm

St. Joseph's Hospital to Open First Proton Radiation Therapy Center in Tampa Bay Area

Retrieved on: 
Friday, November 3, 2023
Radiation, Proton therapy, X-ray, St. Joseph's Hospital, Winter Haven Hospital, Research, Tissue, Risk, Hospital, Fred J. Ansfield, Secondary malignant neoplasm, St. Joseph's Hospital (St. Paul, Minnesota), Cancer, BayCare Ballpark, Patient, Morton Plant Hospital, Medical imaging, Tampa Bay, Proton, Saint Joseph's

TAMPA, Fla., Nov. 3, 2023 /PRNewswire/ -- Construction of the first proton therapy center to open in the Tampa Bay area is set to begin at St. Joseph's Hospital Cancer Institute, bringing technologically advanced treatment closer to home for local cancer patients.

Key Points: 
  • TAMPA, Fla., Nov. 3, 2023 /PRNewswire/ -- Construction of the first proton therapy center to open in the Tampa Bay area is set to begin at St. Joseph's Hospital Cancer Institute , bringing technologically advanced treatment closer to home for local cancer patients.
  • "BayCare is bringing the first proton radiation therapy center to Tampa so patients in our community don't have to drive to Orlando or beyond to get this level of high-quality care."
  • Woods Radiation Therapy Center and proton therapy treatment is expected to be available by fall 2025.
  • Woods Radiation Therapy Center at St. Joseph's Hospital treats more than 900 patients each year using a variety of radiation therapy treatments and state-of-the-art equipment.

FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

Retrieved on: 
Monday, April 17, 2023
Vaccine, Infection, China Biologic Products, Priority review, Graft-versus-host disease, Night sweats, Radiation, Office of Inspector General, U.S. Department of Health and Human Services, Neutrophil, Human services, Public, Tumors of the hematopoietic and lymphoid tissues, Survival, Bone marrow, Weight loss, Cancer, Weakness, Fever, Center for Biologics Evaluation and Research, Food, Cosmetics, Multimedia, Haematopoietic system, Cell, Animal, Rash, Transplant, Incidence, Secondary malignant neoplasm, Hematopoietic stem cell transplantation, Dietary supplement, Patient, Risk, Blood, Immune system, Growth, Vein graft failure, Trial of the century, Fungal infection, Research, B cell, FDA, Heated tobacco product, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DSM-IV codes, Safety, Fatigue, Pharmaceutical industry

"Today's approval is an important advance in cell therapy treatment in patients with blood cancers," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.

Key Points: 
  • "Today's approval is an important advance in cell therapy treatment in patients with blood cancers," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.
  • "Hastening the return of the body's white blood cells can reduce the possibility of serious or overwhelming infection associated with stem cell transplantation.
  • Blood cancers are a form of cancer caused by uncontrolled growth of cells in the blood, disrupting the ability of blood cells to perform their normal functions.
  • Blood cancers can be fatal, with varying survival rates based on multiple factors including the specific type of blood cancer diagnosed.

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Retrieved on: 
Friday, February 17, 2023
DNA, B cell, Immune reconstitution inflammatory syndrome, Secondary malignant neoplasm, Stanford University School of Medicine, Pediatrics, Inborn errors of metabolism, Blood, Stanford University, FA, Patient, Safety, Infection, DNA repair, European Society for Primary Immunodeficiencies, IEWP, Penile ultrasonography, Bone marrow failure, Research, Therapy, Infertility, Risk, Graft-versus-host disease, Toxic epidermal necrolysis, End organ damage, MDS, Haematopoietic system, Mucositis, Transplant, CD117, Fanconi anemia, Allotransplantation, Definitive, Syndrome, Pharmaceutical industry, Dentistry, Jasper

The study is a Phase 1/2 clinical trial ( NCT04784052 ) utilizing briquilimab to treat FA patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.

Key Points: 
  • The study is a Phase 1/2 clinical trial ( NCT04784052 ) utilizing briquilimab to treat FA patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.
  • In the follow-up data series presented, 100% total donor chimerism was achieved through six months for the first patient and at three months for the second patient.
  • Briquilimab was cleared by day 9 after dosing in both patients and no treatment-related adverse events or toxicities were observed.
  • It is also the only proven treatment for the bone marrow failure that occurs in a majority of patients with FA.

Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma

Retrieved on: 
Thursday, December 15, 2022
Melanoma, FLASH, IIA, Food, NDA, Doctor of Philosophy, Skin, Secondary malignant neoplasm, EMA, Patient, Cancer, Research, IB, Index, FDA, Solar cycle 2, European Medicines Agency, Growth, Trial of the century, State, Light, Food and Drug Administration, Risk, Pharmaceutical industry, CTCL

The Company estimates the potential worldwide market for HyBryte to be in excess of $250 million for the treatment of CTCL.

Key Points: 
  • The Company estimates the potential worldwide market for HyBryte to be in excess of $250 million for the treatment of CTCL.
  • HyBryte has received orphan drug and fast track designations from the FDA, as well as orphan designation from the European Medicines Agency (EMA).
  • In the first double-blind treatment cycle, 116 patients received HyBryte treatment (0.25% synthetic hypericin) and 50 received placebo treatment of their index lesions.
  • In the second open-label treatment cycle ( Cycle 2 ), all patients received HyBryte treatment of their index lesions.

Mevion Identifies Site for New Compact Proton Therapy System in Development

Retrieved on: 
Sunday, October 23, 2022
Research, Medical Devices, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Adoption, LinkedIn, Risk, Science, Proton therapy, LINAC, Patient, PBS, Multimedia, Varian Medical Systems, Cancer, Secondary malignant neoplasm, Stanford University Medical Center, Scan (company), CEO, Radiation, Medical imaging, Proton

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that it is developing the MEVION S250-FIT Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS).

Key Points: 
  • Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that it is developing the MEVION S250-FIT Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS).
  • Historically, the size, cost, and inherent complexity of proton technologies have limited the adoption of proton therapy.
  • Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care.
  • Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion was the first company to innovate this new single-room platform and continues to further the science and application of proton therapy.

Ackerman Cancer Center Celebrates 2,000 Patients Treated with Proton Therapy

Retrieved on: 
Thursday, March 31, 2022
Radiology, Health, Oncology, Proton, Risk, Cancer, ACC, Lung, Leadership, Neck, Nursing, Proton therapy, Prostate, Breast, Social, Head, Conference, LinkedIn, Achievement, CEO, Quality of life, Prostate cancer, Science, Secondary malignant neoplasm, Breast cancer, NAPT, Patient, Radiation, Medical imaging, MEVION MEDICAL SYSTEMS, ACKERMAN CANCER CENTER

Ackerman Cancer Center (ACC), the worlds first and only physician-owned proton therapy center, has reached a significant milestone in cancer care with the treatment of their 2,000th proton therapy patient.

Key Points: 
  • Ackerman Cancer Center (ACC), the worlds first and only physician-owned proton therapy center, has reached a significant milestone in cancer care with the treatment of their 2,000th proton therapy patient.
  • The Mevion-equipped center treated its first proton therapy patient in April of 2015 and reached its 1,000th patient milestone in October of 2018.
  • With proton therapy, our patients receive a personalized and precise treatment and enjoy a better quality of life, said Dr. Ackerman, Medical Director of Ackerman Cancer Center.
  • Ackerman Cancer Center will honor their 2,000th proton therapy patient, Mrs. Shosh Orgad, at an upcoming event in Jacksonville, Florida.

Mevion Selected to Equip New Proton Therapy and Research Center in San Antonio

Retrieved on: 
Wednesday, February 9, 2022
Biotechnology, Oncology, Health, Medical Devices, Hospitals, University, Education, Other Health, Proton, University, PBS, University of Texas Health Science Center at San Antonio, LinkedIn, School, Spine, Nursing, Dentistry, Beaumont Hospital, Royal Oak, Proton therapy, Multimedia, University of Alabama, Varian Medical Systems, NCI, Medicine, Science, Time, YouTube, Research, COVID-19, Twitter, Cancer, PI, Heart, Risk, Secondary malignant neoplasm, Technology, Patient, Hospital, MD, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Education, Brain, CEO, Health, University of Texas System, Instagram, Partnership, UT Health San Antonio Cancer Center, Education, Medical imaging, Facebook

Mevion Medical Systems and Proton International announce the selection of the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) to equip the UT Health San Antonio Proton Therapy and Research Center.

Key Points: 
  • Mevion Medical Systems and Proton International announce the selection of the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) to equip the UT Health San Antonio Proton Therapy and Research Center.
  • It will be the first proton therapy system in San Antonio and South Texas to provide this advanced alternative to conventional radiation therapy for cancer.
  • The MEVION S250i with HYPERSCAN has advanced the benefits of proton therapy by enabling faster and sharper delivery of therapeutic radiation.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting

Retrieved on: 
Saturday, December 11, 2021
Health, General Health, Instagram, Infection, U.S. Securities and Exchange Commission, LinkedIn, NK, BLA, FDA, Time-invariant system, Lymphatic system, Cell, Population, Hospital, Private Securities Litigation Reform Act, Nominal interest rate, Haematopoiesis, Hematology, UPMC Children's Hospital of Pittsburgh, COVID-19, Cancer, Single Center, HSCT, SEC, Immunotherapy, Breakthrough therapy, Haematopoietic system, Degenerative disease, Safety, NAM, Patient, Therapy, DFS, Immune system, Security (finance), Bone marrow, Orphan, Facebook, Risk, ASH, Twitter, Division, Secondary malignant neoplasm, Society, Duke University, Pharmaceutical industry, Vaccine, Medical imaging, Blood, EU, Omidubicel, Gamida Cell, OMIDUBICEL, GAMIDA CELL

The robust recovery of the immune system provides rationale for fewer severe bacterial, fungal and viral infections in patients treated with omidubicel.

Key Points: 
  • The robust recovery of the immune system provides rationale for fewer severe bacterial, fungal and viral infections in patients treated with omidubicel.
  • Gamida Cell will present additional clinical updates at ASH including two-year survival data for GDA-201, the companys lead NAM-enabled NK cell therapy, and an analysis of hospital and healthcare resource use for patients treated with omidubicel compared to cord blood transplantation.
  • Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with blood cancers.
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases.

Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom

Retrieved on: 
Monday, November 8, 2021
Medication, Population, Achievement, Skin, Health care, Light, MAA, Melanoma, MHRA, European Union, Doctor of Philosophy, EMA, Food, European Medicines Agency, Union, Trial of the century, Growth, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Secondary malignant neoplasm, Solar cycle 2, Index, Company, IIA, FLASH, Nasdaq, Patient, PIP, Risk, United Kingdom, IB, Pharmaceutical industry

Earlier this year the European Medicines Agency (EMA) also granted a waiver to the Pediatric Investigational Plan requirements for the European Union (EU).

Key Points: 
  • Earlier this year the European Medicines Agency (EMA) also granted a waiver to the Pediatric Investigational Plan requirements for the European Union (EU).
  • With the withdrawal of the United Kingdom (UK) from the EU effective January 1, 2021, the MHRA became the UK's standalone medicines and medical devices regulator.
  • HyBryte has received orphan drug and fast track designations from the U.S. Food and Drug Administration, as well as orphan designation from the EMA.
  • The Phase 3 FLASH trial enrolled a total of 169 patients (166 evaluable) with Stage IA, IB or IIA CTCL.

Mevion Selected to Equip Compact Proton Therapy Center in Kansas City

Retrieved on: 
Monday, October 25, 2021
Hospitals, Health, Medical Devices, Proton, Science, Secondary malignant neoplasm, Annual general meeting, Research, Technology, Industry, Radiation therapy, LinkedIn, Adoption, Patient, McCormick Place, MLC, Risk, Lead, FLASH, Proton therapy, CEO, American Society for Radiation Oncology, Multimedia, Motion, ASTRO, Varian Medical Systems, Sale, Society, Medical imaging

The size and cost of larger proton technologies has been a major impediment to the adoption of proton therapy.

Key Points: 
  • The size and cost of larger proton technologies has been a major impediment to the adoption of proton therapy.
  • Today, new proton therapy centers in the US are almost exclusively compact single-room systems and Mevion is the preferred compact provider in the US.
  • Kansas City Urology Care is the premier center for urology care in Kansas City that assures cutting-edge treatment solutions for all forms of urological conditions.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.